全文获取类型
收费全文 | 40404篇 |
免费 | 3413篇 |
国内免费 | 3328篇 |
出版年
2024年 | 71篇 |
2023年 | 501篇 |
2022年 | 1224篇 |
2021年 | 2018篇 |
2020年 | 1447篇 |
2019年 | 1714篇 |
2018年 | 1643篇 |
2017年 | 1217篇 |
2016年 | 1698篇 |
2015年 | 2515篇 |
2014年 | 2996篇 |
2013年 | 3121篇 |
2012年 | 3746篇 |
2011年 | 3274篇 |
2010年 | 2148篇 |
2009年 | 1729篇 |
2008年 | 2155篇 |
2007年 | 1849篇 |
2006年 | 1720篇 |
2005年 | 1439篇 |
2004年 | 1214篇 |
2003年 | 1136篇 |
2002年 | 962篇 |
2001年 | 729篇 |
2000年 | 588篇 |
1999年 | 623篇 |
1998年 | 390篇 |
1997年 | 329篇 |
1996年 | 370篇 |
1995年 | 311篇 |
1994年 | 344篇 |
1993年 | 209篇 |
1992年 | 296篇 |
1991年 | 246篇 |
1990年 | 232篇 |
1989年 | 157篇 |
1988年 | 111篇 |
1987年 | 98篇 |
1986年 | 81篇 |
1985年 | 87篇 |
1984年 | 61篇 |
1983年 | 46篇 |
1982年 | 44篇 |
1981年 | 29篇 |
1980年 | 19篇 |
1979年 | 28篇 |
1977年 | 16篇 |
1976年 | 18篇 |
1975年 | 15篇 |
1973年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
931.
Jing Lu Mingxin Wen Yurong Huang Xiuquan He Yunshan Wang Qi Wu Zengchun Li Andres Castellanos-Martin Mar Abad Juan J. Cruz-Hernandez Cesar A. Rodriguez Jesus Perez-Losada Jian-Hua Mao Guangwei Wei 《Epigenetics》2013,8(6):571-583
Recently, it has been suggested that C2ORF40 is a candidate tumor suppressor gene in breast cancer. However, the mechanism for reduced expression of C2ORF40 and its functional role in breast cancers remain unclear. Here we show that C2ORF40 is frequently silenced in human primary breast cancers and cell lines through promoter hypermethylation. C2ORF40 mRNA level is significantly associated with patient disease-free survival and distant cancer metastasis. Overexpression of C2ORF40 inhibits breast cancer cell proliferation, migration and invasion. By contrast, silencing C2ORF40 expression promotes these biological phenotypes. Bioinformatics and FACS analysis reveal C2ORF40 functions at G2/M phase by downregulation of mitotic genes expression, including UBE2C. Our results suggest that C2ORF40 acts as a tumor suppressor gene in breast cancer pathogenesis and progression and is a candidate prognostic marker for this disease. 相似文献
932.
Tianjiao Lyu Nan Jia Jieyu Wang Xiaohui Yan Yinhua Yu Zhen Lu Robert C Bast Jr Keqin Hua Weiwei Feng 《Epigenetics》2013,8(12):1330-1346
The initiation of angiogenesis can mark the transition from tumor dormancy to active growth and recurrence. Mechanisms that regulate recurrence in human cancers are poorly understood, in part because of the absence of relevant models. The induction of ARHI (DIRAS3) induces dormancy and autophagy in human ovarian cancer xenografts but produces autophagic cell death in culture. The addition of VEGF to cultures maintains the viability of dormant autophagic cancer cells, thereby permitting active growth when ARHI is downregulated, which mimics the “recurrence” of growth in xenografts. Two inducible ovarian cancer cell lines, SKOv3-ARHI and Hey-ARHI, were used. The expression level of angiogenesis factors was evaluated by real-time PCR, immunohistochemistry, immunocytochemistry and western blot; their epigenetic regulation was measured by bisulfite sequencing and chromatin immunoprecipitation. Six of the 15 angiogenesis factors were upregulated in dormant cancer cells (tissue inhibitor of metalloproteinases-3, TIMP3; thrombospondin-1, TSP1; angiopoietin-1; angiopoietin-2; angiopoietin-4; E-cadherin, CDH1). We found that TIMP3 and CDH1 expression was regulated epigenetically and was related inversely to the DNA methylation of their promoters in cell cultures and in xenografts. Increased H3K9 acetylation was associated with higher TIMP3 expression in dormant SKOv3-ARHI cells, while decreased H3K27me3 resulted in the upregulation of TIMP3 in dormant Hey-ARHI cells. Elevated CDH1 expression during dormancy was associated with an increase in both H3K4me3 and H3K9Ac in two cell lines. CpG demethylating agents and/or histone deacetylase inhibitors inhibited the re-growth of dormant cancer cells, which was associated with the re-expression of anti-angiogenic genes. The expression of the anti-angiogenic genes TIMP3 and CDH1 is elevated during dormancy and is reduced during the transition to active growth by changes in DNA methylation and histone modification. 相似文献
933.
Jiri Neuzil Lan-Feng Dong Jakub Rohlena Jaroslav Truksa Stephen J. Ralph 《Mitochondrion》2013,13(3):199-208
Mitochondria have emerged as an intriguing target for anti-cancer drugs, inherent to vast majority if not all types of tumours. Drugs that target mitochondria and exert anti-cancer activity have become a focus of recent research due to their great clinical potential (which has not been harnessed thus far). The exceptional potential of mitochondria as a target for anti-cancer agents has been reinforced by the discouraging finding that even tumours of the same type from individual patients differ in a number of mutations. This is consistent with the idea of personalised therapy, an elusive goal at this stage, in line with the notion that tumours are unlikely to be treated by agents that target only a single gene or a single pathway. This endows mitochondria, an invariant target present in all tumours, with an exceptional momentum. This train of thoughts inspired us to define a class of anti-cancer drugs acting by way of mitochondrial ‘destabilisation’, termed ‘mitocans’. In this communication, we define mitocans (many of which have been known for a long time) and classify them into several classes based on their molecular mode of action. We chose the targets that are of major importance from the point of view of their role in mitochondrial destabilisation by small compounds, some of which are now trialled as anti-cancer agents. The classification starts with targets at the surface of mitochondria and ending up with those in the mitochondrial matrix. The purpose of this review is to present in a concise manner the classification of compounds that hold a considerable promise as potential anti-cancer drugs. 相似文献
934.
Jordi Muntané Angel J. De la Rosa Luís M. Marín Francisco J. Padillo 《Mitochondrion》2013,13(3):257-262
Nitric oxide (NO) is a lipophillic, highly diffusible, and short-lived physiological messenger which regulates a variety of physiopathological responses. NO may exert its cellular action through cGMP-dependent and cGMP-independent pathways which includes different postranslational modifications. The effect of NO in cancer depends on the activity and localization of NOS isoforms, concentration and duration of NO exposure, cellular sensitivity, and hypoxia/re-oxygenation process. NO regulates critical factors such as the hypoxia inducible factor-1 (HIF-1) and p53 generally leading to growth arrest, apoptosis or adaptation. NO sensitizes hepatoma cells to chemotherapeutic compounds probably through increased p53 and cell death receptor expressions. 相似文献
935.
Brandon Faubert Gino Boily Said Izreig Takla Griss Bozena Samborska Zhifeng Dong Fanny Dupuy Christopher Chambers Benjamin J. Fuerth Benoit Viollet Orval A. Mamer Daina Avizonis Ralph J. DeBerardinis Peter M. Siegel Russell G. Jones 《Cell metabolism》2013,17(1):113-124
- Download : Download high-res image (85KB)
- Download : Download full-size image
936.
937.
938.
Kristen M. Varney Alexandre M. J. J. Bonvin Marzena Pazgier Jakob Malin Wenbo Yu Eugene Ateh Taiji Oashi Wuyuan Lu Jing Huang Marlies Diepeveen-de Buin Joseph Bryant Eefjan Breukink Alexander D. MacKerell Jr Erik P. H. de Leeuw 《PLoS pathogens》2013,9(11)
We have previously reported on the functional interaction of Lipid II with human alpha-defensins, a class of antimicrobial peptides. Lipid II is an essential precursor for bacterial cell wall biosynthesis and an ideal and validated target for natural antibiotic compounds. Using a combination of structural, functional and in silico analyses, we present here the molecular basis for defensin-Lipid II binding. Based on the complex of Lipid II with Human Neutrophil peptide-1, we could identify and characterize chemically diverse low-molecular weight compounds that mimic the interactions between HNP-1 and Lipid II. Lead compound BAS00127538 was further characterized structurally and functionally; it specifically interacts with the N-acetyl muramic acid moiety and isoprenyl tail of Lipid II, targets cell wall synthesis and was protective in an in vivo model for sepsis. For the first time, we have identified and characterized low molecular weight synthetic compounds that target Lipid II with high specificity and affinity. Optimization of these compounds may allow for their development as novel, next generation therapeutic agents for the treatment of Gram-positive pathogenic infections. 相似文献
939.
Young-Jun Park Sung-Jin Yoon Hyun-Woo Suh Dong Oh Kim Jeong-Ran Park Haiyoung Jung Tae-Don Kim Suk Ran Yoon Jeong-Ki Min Hee-Jun Na Seon-Jin Lee Hee Gu Lee Young Ho Lee Hee-Bong Lee Inpyo Choi 《PLoS pathogens》2013,9(10)
Thioredoxin-interacting protein (TXNIP) has multiple functions, including tumor suppression and involvement in cell proliferation and apoptosis. However, its role in the inflammatory process remains unclear. In this report, we demonstrate that Txnip−/− mice are significantly more susceptible to lipopolysaccharide (LPS)-induced endotoxic shock. In response to LPS, Txnip−/− macrophages produced significantly higher levels of nitric oxide (NO) and inducible nitric oxide synthase (iNOS), and an iNOS inhibitor rescued Txnip−/− mice from endotoxic shock-induced death, demonstrating that NO is a major factor in TXNIP-mediated endotoxic shock. This susceptibility phenotype of Txnip−/− mice occurred despite reduced IL-1β secretion due to increased S-nitrosylation of NLRP3 compared to wild-type controls. Taken together, these data demonstrate that TXNIP is a novel molecule that links NO synthesis and NLRP3 inflammasome activation during endotoxic shock. 相似文献
940.
Xue Wang Fengting Xu Jiasen Liu Bingquan Gao Yanxin Liu Yujia Zhai Jun Ma Kai Zhang Timothy S. Baker Klaus Schulten Dong Zheng Hai Pang Fei Sun 《PLoS pathogens》2013,9(1)
Rabbit hemorrhagic disease, first described in China in 1984, causes hemorrhagic necrosis of the liver. Its etiological agent, rabbit hemorrhagic disease virus (RHDV), belongs to the Lagovirus genus in the family Caliciviridae. The detailed molecular structure of any lagovirus capsid has yet to be determined. Here, we report a cryo-electron microscopic (cryoEM) reconstruction of wild-type RHDV at 6.5 Å resolution and the crystal structures of the shell (S) and protruding (P) domains of its major capsid protein, VP60, each at 2.0 Å resolution. From these data we built a complete atomic model of the RHDV capsid. VP60 has a conserved S domain and a specific P2 sub-domain that differs from those found in other caliciviruses. As seen in the shell portion of the RHDV cryoEM map, which was resolved to ∼5.5 Å, the N-terminal arm domain of VP60 folds back onto its cognate S domain. Sequence alignments of VP60 from six groups of RHDV isolates revealed seven regions of high variation that could be mapped onto the surface of the P2 sub-domain and suggested three putative pockets might be responsible for binding to histo-blood group antigens. A flexible loop in one of these regions was shown to interact with rabbit tissue cells and contains an important epitope for anti-RHDV antibody production. Our study provides a reliable, pseudo-atomic model of a Lagovirus and suggests a new candidate for an efficient vaccine that can be used to protect rabbits from RHDV infection. 相似文献